These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. 2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis. Pereira IA; Mota LM; Cruz BA; Brenol CV; Fronza LS; Bertolo MB; Freitas MV; Silva NA; Louzada-Junior P; Giorgi RD; Lima RA; Pinheiro Gda R; Rev Bras Reumatol; 2012 Aug; 52(4):474-95. PubMed ID: 22885417 [TBL] [Abstract][Full Text] [Related]
28. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384 [TBL] [Abstract][Full Text] [Related]
29. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901 [TBL] [Abstract][Full Text] [Related]
30. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Goldenberg MM Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256 [TBL] [Abstract][Full Text] [Related]
31. Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Gaujoux-Viala C; Gossec L; Cantagrel A; Dougados M; Fautrel B; Mariette X; Nataf H; Saraux A; Trope S; Combe B; Joint Bone Spine; 2014 Jul; 81(4):287-97. PubMed ID: 24986683 [TBL] [Abstract][Full Text] [Related]
32. [Long-term drug treatment of chronic polyarthritis: current status and perspectives]. Wollenhaupt J; Langer HE Wien Med Wochenschr; 1990 Jun; 140(12):324-33. PubMed ID: 2204217 [TBL] [Abstract][Full Text] [Related]
34. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599 [TBL] [Abstract][Full Text] [Related]
35. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum; 1996 May; 39(5):713-22. PubMed ID: 8639167 [TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774 [TBL] [Abstract][Full Text] [Related]
38. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Schiff MH; Whelton A Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283 [TBL] [Abstract][Full Text] [Related]
39. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Yazici Y; Shi N; John A Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774 [TBL] [Abstract][Full Text] [Related]
40. Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. Ho CTK; Mok CC; Cheung TT; Kwok KY; Yip RML; Clin Rheumatol; 2019 Dec; 38(12):3331-3350. PubMed ID: 31485846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]